Skip to main content
SpringerLink
Log in

Whole-genome sequencing cost effective in stage III/IV NSCLC?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2020 euros

Reference

  • Simons MJHG, et al. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer PharmacoEconomics : 18 Aug 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01073-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Whole-genome sequencing cost effective in stage III/IV NSCLC?. PharmacoEcon Outcomes News 886, 29 (2021). https://doi.org/10.1007/s40274-021-08007-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08007-4

Search

Navigation